Study	Reason for exclusion
Assanovich 2021	Ineligible study design: a description of properties of fluvoxamine
Brown University 2021	Ineligible study design: not original study publication, rather a commentary on how fluvoxamine may limit deterioration from COVID‐19
Glebov 2021	Ineligible study design: a highlight of protective effect of fluvoxamine antidepressant against COVID‐19, highlighting therapeutic and prophylactic potential
Hashimoto 2021	Ineligible study design: a commentary on mechanisms of action of fluvoxamine for COVID‐19
Khosravi 2022	Ineligible study design: a narrative review
Marcec 2021	Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID‐19 treatment
McCarthy 2021	Ineligible study design: paper reviewed the pleiotropic properties of fluvoxamine and explored how the drug may be used to treat the inflammatory sequelae of COVID‐19 in the future
Medical Letter 2021	Ineligible study design: a commentary on properties of fluvoxamine
Murchu 2021	Ineligible study design: not an original publication
NCT04711863	Suspended Trial: trial was suspended due to closure of the main treatment centre
Seftel 2021	Ineligible study design: a prospective cohort study in real‐world experience using fluvoxamine
Sukhatme 2021	Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID‐19 treatment